Why Pfizer and BioNTech stocks popped Wednesday

The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

| More on:
woman waering face mask holding vial of covid-19 vaccine

Image source: Getty Images

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) climbed on Wednesday after the pharmaceutical titan and biotech announced a major development in the battle against COVID-19. As of 2:40 p.m. EST, Pfizer's and BioNTech's stocks were up 3% and 5.6%, respectively.

So what

A phase 3 trial showed Pfizer's and BioNTech's vaccine candidate BNT162b2 to be as much as 95% effective at preventing COVID-19. And importantly, BNT162b2 was generally well tolerated with no serious safety concerns observed among the study's participants to date. This promising data prompted the U.K. government to grant emergency authorization for the COVID-19 vaccine. 

"Today's Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19," Pfizer CEO Albert Bourla said in a press release. "This authorization is a goal we have been working toward since we first declared that science will win."

Pfizer and BioNTech have agreed to supply the U.K. with 40 million doses of the vaccine. The healthcare companies will begin delivering the vaccine immediately, with the first doses expected to arrive in the coming days. 

Now what 

The U.K.'s decision is a major step forward in the war against the dangerous disease. COVID-19 case counts remain at alarmingly high levels in many areas of the world. A safe and effective vaccine could help to slow the spread of the disease and eventually help to bring about an end to the pandemic.

Pfizer and BioNTech stand ready to deliver their vaccine to more countries in the weeks ahead. They have requested emergency authorization from health regulators in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are expected to announce their decisions later this month.

"As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world," Bourla said. "With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic."

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News